EX-10.20B



 Exhibit 10.20(B) 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  

			
	CONFIDENTIAL		





 AMENDMENT NO. 1 

to the 
 Multi-Product License
Agreement 
 dated 22 August 2012 

between 
 LONZA SALES AG 

and 
 ONCOMED PHARMACEUTICALS, INC


  
 1 









			
	CONFIDENTIAL		





 THIS AMENDMENT is made the day of January 22 2014 

BETWEEN 
 LONZA SALES AG incorporated and registered in
Switzerland whose registered office is at Muenchensteinerstrasse 38, CH-4002, Basel, Switzerland (hereinafter referred to as “Lonza”) and 

ONCOMED PHARMACEUTICALS, INC., incorporated in Delaware whose office is at 800 Chesapeake Drive, Redwood City, CA 94063, USA (hereinafter referred to as
“OncoMed”) 
 WHEREAS 
  

	A.	OncoMed and Lonza entered into a Multi-Product License Agreement dated 22 August 2012 (hereinafter referred to as the “Agreement”), in respect of the use by OncoMed of Lonza’s proprietary System (as
defined in the Agreement). 

  

	B.	Lonza now wishes to clarify the content of Schedule 2 in the Agreement. 

  

	C.	Lonza and OncoMed now wish to amend the terms of the Agreement. 

 NOW THEREFORE in consideration of the mutual
promises and covenants contained herein, and other good and valuable consideration the receipt of which is hereby acknowledged, it is hereby agreed by the parties to amend the Agreement as follows: 

 

	1.	The words and phrases defined in the Agreement shall have the same meanings in this Amendment. 

  

	2.	Schedule 2 of the Agreement is hereby deleted in its entirety and replaced by the Schedule 2 annexed hereto. 

  

	3.	Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect. 


  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

2 








 IN WITNESS WHEREOF the parties have caused this Amendment No.1 to be executed by their respective representatives
thereunto duly authorised as of the day and year first above written. 
  

							
					
				
	 Signed for and on behalf of
 LONZA SALES
AG
						/s/ Sven Frie
							Sven Frie
							 Director

Sales & Business Development

							TITLE


							
			
					
				
	 Signed for and on behalf of
 LONZA SALES
AG
						/s/ Cordula Altekrüger
							Cordula Altekrüger
							Legal Counsel
							TITLE


							
			
					
				
	 Signed for and behalf of
 ONCOMED
PHARMACEUTICALS, INC.
						/s/ John Lewicki
							EVP, CSO
							TITLE


  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3 








 SCHEDULE 2 

PRODUCTS 
 [***] 

  
 [***] Certain information in this
document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4